A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

Also called NCT02616666

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 632 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02616666
  • EudraCT 2015-001873-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02616666. Randomized; no masking; primary purpose treatment. Start 2016-08-25 (actual); primary completion 2025-12-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
Acronym
DECIDE
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Standard of Care
Lead sponsor
University of Liverpool (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Clinical Practice Research Datalink (class: other government)

Record details

Record id
cardio:ct-nct02616666
Content hash
caca5c6ba3ed5e83b572a9e615e4f64f888d873e1bc710f97159b956219384f5